Werewolf Therapeutics (HOWL)
(Delayed Data from NSDQ)
$2.94 USD
+0.20 (7.30%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $2.94 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.94 USD
+0.20 (7.30%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $2.94 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
All You Need to Know About Werewolf Therapeutics (HOWL) Rating Upgrade to Buy
by Zacks Equity Research
Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
How Much Upside is Left in Werewolf Therapeutics, Inc. (HOWL)? Wall Street Analysts Think 92.37%
by Zacks Equity Research
The consensus price target hints at a 92.4% upside potential for Werewolf Therapeutics, Inc. (HOWL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 23.26% and 45.42%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
TScan Therapeutics, Inc. (TCRX) delivered earnings and revenue surprises of 30% and 145.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength?
by Zacks Equity Research
Exelixis (EXEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 65.85% and 164.95%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Seer, Inc. (SEER) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 2.63% and 25.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Curis (CRIS) delivered earnings and revenue surprises of 0% and 14.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for July 26th
by Zacks Equity Research
ANGI, SFIX, ZVIA, ZYME and HOWL have been added to the Zacks Rank #1 (Strong Buy) List on July 26, 2023.
Will AbbVie's (ABBV) New Drugs Make Up for Low Humira Sales?
by Zacks Equity Research
In its Q2 earnings results, AbbVie's (ABBV) Skyrizi and Rinvoq sales are expected to have made up for the declining Humira sales following the loss of U.S. exclusivity.
Mirati (MRTX) Down 7% on CHMP's Opinion on Krazati Filing
by Zacks Equity Research
Per the CHMP, Mirati's (MRTX) regulatory filing for Krazati in KRASG12C mutated NSCLC does not fulfill certain requirements to support a conditional marketing authorization.
Merck (MRK) Keytruda Advanced Cervical Cancer Study Meets Goal
by Zacks Equity Research
Interim data from a late-stage study, evaluating Merck's (MRK) Keytruda as a combination therapy, met one of its primary endpoints of progression-free survival.
Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 30.61% and 46.36%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 33.90% and 131.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for January 20th
by Zacks Equity Research
NBSE, PRTG, RELL, HOWL and PATH have been added to the Zacks Rank #1 (Strong Buy) List on January 20, 2022.
New Strong Buy Stocks for January 18th
by Zacks Equity Research
DTEGY, CYN, OKTA, HOWL and ONCY have been added to the Zacks Rank #1 (Strong Buy) List on January 18, 2022.
Werewolf Therapeutics, Inc. (HOWL) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 33.33% and 18.53%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Consider Investing in JAZZ Stock Now
by Zacks Equity Research
JAZZ's new drugs like Xywav, Rylaze and Zepzelca, along with the recently-acquired drugs, are expected to generate 65% of product revenues in 2022.
JAZZ's Late-Stage Multiple Sclerosis Study on Nabiximols Fails
by Zacks Equity Research
JAZZ's phase III study evaluating nabiximols oromucosal spray for clinical measures of spasticity in multiple sclerosis patients fails to meet the primary endpoint.
JAZZ Stock Surges Almost 30% YTD: What's Driving the Rally?
by Zacks Equity Research
Strong performance of JAZZ's Xywav and new oncology drugs along with acquired drugs reduced dependence on Xyrem, which will face generic competition shortly.
JAZZ Inks Deal With Werewolf to Add Oncology Candidate
by Zacks Equity Research
Jazz (JAZZ) signs an agreement to gain rights to Werewolf's engineered cytokine pro-drug candidate WTX-613. The candidate has the potential to treat a wide range of cancer types.
Werewolf (HOWL) Up on Deal With Merck for Solid Tumor Study
by Zacks Equity Research
Werewolf Therapeutics (HOWL) inks a collaboration and supply agreement with Merck to evaluate its candidate, WTX-124, in combination with Keytruda, for treating solid tumors. Stock up.